Institut Curie

This study tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus chemotherapy in 81 women with triple negative breast cancer. It includes two groups: those with early-stage cancer and those with advanced (metastatic) cancer. The goal is to see if the …

This study tests whether combining chemotherapy with local treatments can save the eyes of children with retinoblastoma, a rare eye cancer. About 133 children with different stages of the disease received chemotherapy drugs followed by heat therapy or other local treatments. The …

This study tests two drugs, pembrolizumab and lenvatinib, in people with metastatic uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can slow tumor growth. The trial includes two groups: those who have not had a prior treatment called Teben…

This study tests whether adding either ibrutinib or lenalidomide to standard chemotherapy can improve treatment for adults (18-65) with newly diagnosed primary central nervous system lymphoma, a rare brain cancer. The trial first finds safe doses, then randomly assigns patients t…

This early-stage study tests a new drug called PEP-010, given alone or with standard chemotherapies (paclitaxel or gemcitabine), in people with metastatic solid tumors that are no longer responding to standard treatments. The main goals are to check safety and find the right dose…

This study checks if a blood test that looks for tumor DNA can find HPV-positive pelvic cancers (like cervical or anal cancer) coming back earlier than usual scans. About 172 people who finished treatment for stage II or III cancer will give blood samples during follow-up visits.…

This study looks at whether regular MRI scans can find new head, neck, or brain cancers early in people with hereditary retinoblastoma who had radiation therapy. About 88 participants who are at least 7 years old and had radiation 5+ years ago will get MRI screenings. The goal is…